Zhou Jin, Tripathi Madhulika, Ho Jia Pei, Widjaja Anissa Anindya, Shekeran Shamini Guna, Camat Macalinao Dominique, James Anne, Wu Yajun, Ching Jianhong, Kovalik Jean-Paul, Lim Kiat-Hon, Cook Stuart Alexander, Bay Boon-Huat, Singh Brijesh Kumar, Yen Paul Michael
Program of Cardiovascular & Metabolic Disorders, Duke-NUS Medical School, Singapore, Singapore.
Department of Pathology, Singapore General Hospital, Singapore, Singapore.
Thyroid. 2022 Jun;32(6):725-738. doi: 10.1089/thy.2021.0621. Epub 2022 May 25.
Nonalcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, lobular inflammation, and fibrosis. Thyroid hormone (TH) reduces steatosis; however, the therapeutic effect of TH on NASH-associated inflammation and fibrosis is not known. This study examined the therapeutic effect of TH on hepatic inflammation and fibrosis during NASH and investigated THs molecular actions on autophagy and mitochondrial biogenesis. HepG2-TRβ cells were treated with bovine serum albumin-conjugated palmitic acid (PA) to mimic lipotoxic conditions . Mice with NASH were established by feeding C57BL/6J mice Western diet with 15% fructose in drinking water for 16 weeks. These mice were administered triiodothyronine (T3)/thyroxine (T4) supplemented in drinking water for the next eight weeks. In cultured HepG2-TRβ cells, TH treatment increased mitochondrial respiration and fatty acid oxidation under basal and PA-treated conditions, as well as decreased lipopolysaccharides and PA-stimulated inflammatory and fibrotic responses. In a dietary mouse model of NASH, TH administration decreased hepatic triglyceride content (3.19 ± 0.68 vs. 8.04 ± 0.42 mM/g liver) and hydroxyproline (1.44 ± 0.07 vs. 2.58 ± 0.30 mg/g liver) when compared with mice with untreated NASH. Metabolomics profiling of lipid metabolites showed that mice with NASH had increased triacylglycerol, diacylglycerol, monoacylglycerol, and hepatic cholesterol esters species, and these lipid species were decreased by TH treatment. Mice with NASH also showed decreased autophagic degradation as evidenced by decreased transcription Factor EB and lysosomal protease expression, and accumulation of LC3B-II and p62. TH treatment restored the level of lysosomal proteins and resolved the accumulation of LC3B-II and p62. Impaired mitochondrial biogenesis was also restored by TH. The simultaneous restoration of autophagy and mitochondrial biogenesis by TH increased β-oxidation of fatty acids. Additionally, the elevated oxidative stress and inflammasome activation in NASH liver were also decreased by TH. In a mouse model of NASH, TH restored autophagy and mitochondrial biogenesis to increase β-oxidation of fatty acids and to reduce lipotoxicity, oxidative stress, hepatic inflammation, and fibrosis. Activating thyroid hormone receptor in the liver may represent an effective strategy for NASH treatment.
非酒精性脂肪性肝炎(NASH)的特征是肝脂肪变性、小叶炎症和纤维化。甲状腺激素(TH)可减轻脂肪变性;然而,TH对NASH相关炎症和纤维化的治疗效果尚不清楚。本研究检测了TH对NASH期间肝脏炎症和纤维化的治疗效果,并研究了TH对自噬和线粒体生物发生的分子作用。用牛血清白蛋白偶联的棕榈酸(PA)处理HepG2-TRβ细胞以模拟脂毒性条件。通过给C57BL/6J小鼠喂食含15%果糖的西方饮食并持续16周来建立NASH小鼠模型。在接下来的八周里,给这些小鼠饮用添加了三碘甲状腺原氨酸(T3)/甲状腺素(T4)的水。在培养的HepG2-TRβ细胞中,TH处理在基础条件和PA处理条件下均增加了线粒体呼吸和脂肪酸氧化,同时降低了脂多糖和PA刺激的炎症和纤维化反应。在NASH的饮食小鼠模型中,与未治疗的NASH小鼠相比,TH给药降低了肝脏甘油三酯含量(3.19±0.68 vs. 8.04±0.42 mM/g肝脏)和羟脯氨酸含量(1.44±0.07 vs. 2.58±0.30 mg/g肝脏)。脂质代谢物的代谢组学分析表明,NASH小鼠的三酰甘油、二酰甘油、单酰甘油和肝脏胆固醇酯种类增加,而TH处理使这些脂质种类减少。NASH小鼠还表现出自噬降解减少,这可通过转录因子EB和溶酶体蛋白酶表达降低以及LC3B-II和p62的积累来证明。TH处理恢复了溶酶体蛋白水平,并解决了LC3B-II和p62的积累问题。TH还恢复了受损的线粒体生物发生。TH同时恢复自噬和线粒体生物发生增加了脂肪酸的β氧化。此外,TH还降低了NASH肝脏中升高的氧化应激和炎性小体激活。在NASH小鼠模型中,TH恢复了自噬和线粒体生物发生,以增加脂肪酸的β氧化并降低脂毒性、氧化应激、肝脏炎症和纤维化。激活肝脏中的甲状腺激素受体可能是治疗NASH的有效策略。